Recently, Guangdong Tai En Kang Medical Co., Ltd. (hereinafter referred to as "the Company") announced that its subsidiary CKBA has completed the first subject enrollment for the Phase II clinical trial of CKBA cream for pediatric vitiligo (hereinafter referred to as "NB-UVB") in children aged 2-12 years.
301263SZSE
Announcement on the Completion of the First Subject Enrollment for CKBA Cream in Pediatric Vitiligo Phase II Clinical Trial
✨ AI Summary
This announcement details the completion of the first subject enrollment for the Phase II clinical trial of CKBA cream for pediatric vitiligo. The trial targets children aged 2-12 years. The study aims to evaluate the safety and efficacy of the treatment. The company emphasizes the ongoing progress and future developments related to this project.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.